These findings support the efficacy of third‐generation EGFR‐TKIs in patients with LMC, which is in line with previously published data.21, 22 Approval of third‐generation EGFR‐TKIs as a first‐line chemotherapeutic regimen in EGFR‐mutant adenocarcinoma will confer a further survival benefit in patients with LMC from NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.